NCT00336544View on ClinicalTrials.gov

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

522

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Pneumonia
Interventions
DRUG

Cethromycin

Cethromycin 300 mg once per day (QD) for 7 days, administered orally

DRUG

Clarithromycin

Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally

Trial Locations (13)

60517

ARGENTINA - Advanced Life Sciences, Woodridge

BULGARIA - Advanced Life Sciences, Woodridge

CHILE - Advanced Life Sciences, Woodridge

CROATIA - Advanced Life Sciences, Woodridge

ESTONIA - Advanced Life Sciences, Woodridge

GERMANY - Advanced Life Sciences, Woodridge

HUNGARY - Advanced Life Sciences, Woodridge

ISRAEL - Advanced Life Sciences, Woodridge

PERU - Advanced Life Sciences, Woodridge

POLAND - Advanced Life Sciences, Woodridge

ROMANIA - Advanced Life Sciences, Woodridge

THE NETHERLANDS - Advanced Life Sciences, Woodridge

UKRAINE - Advanced Life Sciences, Woodridge

Sponsors
All Listed Sponsors
lead

Advanced Life Sciences, Inc.

INDUSTRY

NCT00336544 - Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia | Biotech Hunter | Biotech Hunter